NO -->|"protects_against"| Stroke NO -->|"reduces"| Ischemia NOS3 -->|"therapeutic_for"| MS Autophagy -->|"promotes"| Neuroprotection NFE2L2 -->|"promotes"| Neuroprotection
...
NOS3 — Nitric Oxide Synthase 3
Introduction
Pathway Diagram
Mermaid diagram (expand to render)
Nos3 — Nitric Oxide Synthase 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NOS3 (Nitric Oxide Synthase 3), also known as endothelial nitric oxide synthase (eNOS), is a gene located on chromosome 7q36 that encodes the endothelial isoform of nitric oxide synthase. This enzyme is primarily expressed in vascular endothelial cells where it produces nitric oxide (NO) that regulates blood flow, blood pressure, and vascular homeostasis.
Function
NOS3 produces nitric oxide in endothelial cells:
Regulates vascular tone and blood pressure
Controls blood flow to the brain (cerebral circulation)
Inhibits platelet adhesion and aggregation
Protects against atherosclerosis
Regulates angiogenesis (new blood vessel formation)
NOS3 is distinct from NOS1 (neuronal) and NOS2 (indcible) isoforms in its regulation - it is constitutively expressed and primarily activated by calcium/calmodulin and phosphorylation.
Disease Associations
Alzheimer's Disease
NOS3 dysfunction may contribute to AD pathogenesis:
Reduced cerebral blood flow in AD patients
Vascular contributions to cognitive impairment
Endothelial dysfunction and [blood-brain barrier](/entities/blood-brain-barrier) breakdown
Interactions with amyloid pathology
Vascular Dementia
NOS3 plays a key role in cerebral vascular function
Endothelial NO deficiency may contribute to vascular cognitive impairment
Reduced NO affects learning and memory
Stroke
NOS3 is protective in acute ischemic stroke
NO maintains cerebral blood flow
Endothelial dysfunction increases stroke risk
Therapeutic Implications
NOS3 activity can be enhanced by statins, ACE inhibitors, and exercise
L-arginine supplementation has been explored
Targeting endothelial dysfunction in AD is an active research area
Key Publications
H从前 et al. (2007). "NOS3 polymorphisms and Alzheimer's disease." Neurosci Lett. PMID: 17321678(https://pubmed.ncbi.nlm.nih.gov/17321678/)
Katusic et al. (2009). "Endothelial nitric oxide synthase in vascular disease." Ann Rev Med. PMID: 18729729(https://pubmed.ncbi.nlm.nih.gov/18729729/)
The study of Nos3 — Nitric Oxide Synthase 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Dudzinski DM, et al, The regulation and pharmacology of endothelial nitric oxide synthase (2006)](https://pubmed.ncbi.nlm.nih.gov/16402905/)
[Balligand JL, et al, Nitric oxide synthase in the heart (2009)](https://pubmed.ncbi.nlm.nih.gov/19524591/)
[Kone BC, et al, NOS3 gene therapy for heart failure (2012)](https://pubmed.ncbi.nlm.nih.gov/22233551/)
[Godecke A, et al, Coronary vessel development (2002)](https://pubmed.ncbi.nlm.nih.gov/12411389/)
[Huang PL, et al, eNOS and cerebrovascular function (2001)](https://pubmed.ncbi.nlm.nih.gov/11506884/)
Pathway Diagram
The following diagram shows the key molecular relationships involving NOS3 — Nitric Oxide Synthase 3 discovered through SciDEX knowledge graph analysis: